Background
The manufacturer of bendamustine (Napp Pharmaceuticals) was invited to submit evidence for this single technology appraisal (STA) in May 2010.
In June 2010, the manufacturer informed NICE that it would not be making an evidence submission because it was unable to identify relevant sources of clinical evidence suitable for a NICE appraisal in people with rituximab-refractory disease. The manufacturer indicated that further research was ongoing but data would not be available in a time frame that would allow NICE to produce timely guidance.
NICE has therefore terminated this single technology appraisal.